RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Taysha Gene Therapies Stock

Taysha Gene Therapies EBIT 2024

Taysha Gene Therapies EBIT

-90.41 M USD

Ticker

TSHA

ISIN

US8776191061

WKN

A2QCJL

In 2024, Taysha Gene Therapies's EBIT was -90.41 M USD, a 26.67% increase from the -71.37 M USD EBIT recorded in the previous year.

The Taysha Gene Therapies EBIT history

YEAREBIT (undefined USD)
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-

Taysha Gene Therapies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Taysha Gene Therapies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Taysha Gene Therapies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Taysha Gene Therapies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Taysha Gene Therapies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Taysha Gene Therapies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Taysha Gene Therapies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Taysha Gene Therapies’s growth potential.

Taysha Gene Therapies Revenue, EBIT and net profit per share

DateTaysha Gene Therapies RevenueTaysha Gene Therapies EBITTaysha Gene Therapies Net Income
2029e506.7 M undefined0 undefined154.69 M undefined
2028e156.2 M undefined-31.24 M undefined-62.71 M undefined
2027e44.37 M undefined-84.29 M undefined-104.52 M undefined
2026e5.29 M undefined-98.41 M undefined-92.4 M undefined
2025e5.34 M undefined-102.95 M undefined-87.59 M undefined
2024e8.54 M undefined-90.41 M undefined-80.61 M undefined
202315.45 M undefined-71.37 M undefined-111.57 M undefined
20222.5 M undefined-126.03 M undefined-166.01 M undefined
20210 undefined-173.27 M undefined-174.52 M undefined
20200 undefined-43 M undefined-60.01 M undefined
20190 undefined-1.12 M undefined-1.12 M undefined

Taysha Gene Therapies stock margins

The Taysha Gene Therapies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Taysha Gene Therapies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Taysha Gene Therapies.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Taysha Gene Therapies's sales revenue. A higher gross margin percentage indicates that the Taysha Gene Therapies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Taysha Gene Therapies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Taysha Gene Therapies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Taysha Gene Therapies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Taysha Gene Therapies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Taysha Gene Therapies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Taysha Gene Therapies Margin History

Taysha Gene Therapies Gross marginTaysha Gene Therapies Profit marginTaysha Gene Therapies EBIT marginTaysha Gene Therapies Profit margin
2029e0 %0 %30.53 %
2028e0 %-20 %-40.15 %
2027e0 %-189.99 %-235.59 %
2026e0 %-1,861.42 %-1,747.59 %
2025e0 %-1,927.87 %-1,640.21 %
2024e0 %-1,059.26 %-944.41 %
20230 %-461.94 %-722.06 %
20220 %-5,041.2 %-6,640.4 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %

Taysha Gene Therapies Aktienanalyse

What does Taysha Gene Therapies do?

Taysha Gene Therapies Inc. is a biopharmaceutical company based in Dallas, Texas, focused on discovering and developing gene therapies for severe neurological disorders. The company was founded in 2019 by leading pharmaceutical entrepreneur RA Capital Management and gene therapy developer Dr. Steven Gray. Taysha Gene Therapies' business model is based on the belief that gene therapy has the potential to revolutionize medicine. The company is dedicated to developing gene therapies that can be used to treat rare genetic diseases, particularly pediatric diseases that have had limited or no treatment options. Their goal is to create innovative therapeutic approaches to improve the lives of affected patients and their families. To achieve this, the company conducts extensive research and development work, addressing the challenging questions and challenges in their field. The biggest hurdle in gene therapy development is the need to tailor treatments to the specific defects of individual patients, requiring personalized therapy. Taysha Gene Therapies addresses this issue through the use of AAV gene therapies, which provide a versatile tool and allow the company to diversify. Currently, the company has four different divisions focused on developing gene therapies for rare diseases. Their first priority is TSHA-101, a gene therapy targeting Angelman syndrome, a genetic disorder that occurs in babies and toddlers and can cause epileptic seizures, developmental delays, sleep disorders, and speech problems. Taysha Gene Therapies is also working on therapies for Tay-Sachs and GM1 gangliosidosis, which are also rare and severe diseases. Additionally, the company is developing therapies for Rett syndrome. Taysha Gene Therapies aims to make global progress in the field of neuropsychiatric and neurological disorders by setting new standards and creating innovative concepts. The company collaborates with leading geneticists, scientists, and neurologists to incorporate the latest technologies in gene therapy development. They have the potential to elevate the treatment of rare genetic diseases that have had limited or no treatment options. In their efforts to improve patient care, Taysha Gene Therapies has formed partnerships with other companies and institutions. In March 2020, they established partnerships with UT Southwestern, RCPD, and AveXis to facilitate the exchange of data and expertise on selected treatment options. This collaboration aims to accelerate progress in gene therapy and develop new therapies and technologies that enhance patient treatment and quality of life. Overall, Taysha Gene Therapies is engaged in exciting and innovative work focused on implementing gene therapies for rare genetic diseases. With their innovative approaches to therapy concept development, partnerships with leading institutions, and excellent collaboration with other companies, they aim to make a significant contribution to improving healthcare. Output: Taysha Gene Therapies Inc. is a biopharmaceutical company based in Dallas, Texas. It focuses on discovering and developing gene therapies for severe neurological disorders, particularly rare genetic diseases in children. The company aims to improve the lives of patients and their families through innovative therapies. It collaborates with experts and uses cutting-edge technologies. Taysha Gene Therapies also partners with other organizations to accelerate progress and improve patient care. Its mission is to revolutionize medicine and contribute to healthcare improvement. Taysha Gene Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Taysha Gene Therapies's EBIT

Taysha Gene Therapies's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Taysha Gene Therapies's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Taysha Gene Therapies's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Taysha Gene Therapies’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Taysha Gene Therapies stock

How much did Taysha Gene Therapies achieve in EBIT for the current year?

In the current year, Taysha Gene Therapies has achieved an EBIT of -90.41 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Taysha Gene Therapies.

How has the EBIT of Taysha Gene Therapies developed in recent years?

The EBIT of Taysha Gene Therapies has increased by 26.667% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Taysha Gene Therapies?

The EBIT of Taysha Gene Therapies is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Taysha Gene Therapies pay?

Over the past 12 months, Taysha Gene Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Taysha Gene Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Taysha Gene Therapies?

The current dividend yield of Taysha Gene Therapies is .

When does Taysha Gene Therapies pay dividends?

Taysha Gene Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Taysha Gene Therapies?

Taysha Gene Therapies paid dividends every year for the past 0 years.

What is the dividend of Taysha Gene Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Taysha Gene Therapies located?

Taysha Gene Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taysha Gene Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taysha Gene Therapies from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Taysha Gene Therapies pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Taysha Gene Therapies in the year 2023?

In the year 2023, Taysha Gene Therapies distributed 0 USD as dividends.

In which currency does Taysha Gene Therapies pay out the dividend?

The dividends of Taysha Gene Therapies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Taysha Gene Therapies

Our stock analysis for Taysha Gene Therapies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taysha Gene Therapies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.